Recently, the Shandong Provincial Medical Security Bureau and the Shandong Provincial Health Commission jointly issued the “Notice on the Implementation of the Selected Results of the Centralized Drug Procurement (Insulin Special) organized by the State” (hereinafter referred to as the “Notice”), pointing out that the sixth The results of the batch of state-organized centralized drug procurement (insulin special project) will be implemented on May 26 this year. The province will participate in public medical institutions (including military medical institutions stationed in Shandong, the same below) and designated medical insurance societies that participate in state-organized insulin centralized procurement. Set up medical institutions (hereinafter referred to as “medical institutions”), execute the results of the selected insulin collection, and sell the selected insulin products to patients.
The “Notice” requires that before May 20, the selected products will be listed on the Internet at the selected price on the provincial centralized procurement platform for medicines and equipment for medical institutions to purchase appropriate amount of selected products for stocking. Relevant medical institutions and selected enterprises complete the signing of purchase and sales agreements through the provincial centralized procurement platform for medicines and equipment.
According to the principle of localized management, the medical insurance departments of each city guide the selected medical institutions represented by the drug procurement consortium to sign a unified purchase and sale agreement with the selected manufacturers. The purchase cycle is 2 years, and the purchase and sale agreement is signed once a year.
The “Notice” also released five major supporting measures to implement the agreed purchase volume, do a good job in the connection of medical insurance payment policies, promote rational drug use in medical institutions, implement incentive and restraint policies, and strengthen monitoring of contract performance to ensure that the selected products enter the hospital. Purchasing according to the agreed purchase volume, standardizing clinical drug use behavior, improving drug use level, guiding medical institutions to use selected products, and promoting drug safety.
Average drop of 48% for selected products in national centralized insulin collection
In the centralized drug procurement completed in November last year, 42 insulin products were selected through bidding. According to the demand put forward by 32,000 medical institutions before the centralized procurement, the demand for centralized insulin procurement in my country exceeds 200 million, involving an amount of about 17 billion yuan. Based on the 3 ml specification of each insulin injection, the price of the selected products is reduced to Each piece is below 80 yuan, and some selected products are below 20 yuan each.
The average price of the selected products will be reduced by 48%, which is expected to save an annual cost of 9 billion yuan, which will benefit 10 million insulin patients nationwide.